Content
11/29/2023
American Fork, UT USA
Biolexis Therapeutics
completed $10 million Series A Round funding. Investors include
Clarke Capital Partners.
About
Moleculern™ – The Next Evolution in Drug Discovery
Screening each Moleculern™ fragment against a curated protein target library has resulted in 600K real/empirical data points and scaffold-like compounds that can be used to design new drug candidates and to accelerate the discovery process.
Our empirically rich Moleculern™ technology is rapidly creating, discovering, and developing novel pre-clinical to clinical stage agents. Our modern chemical biology approach coupled with our advanced machine learning and AI-backed platform accelerates discoveries by mapping hot-spots, computing ligand properties and building accurate empirical models which translate into active, safe, and efficacious novel chemical entities (NCEs) of future medicines.
Biolexis is developing better and safer drugs faster through Moleculern™:
Accelerates drug discovery/development to new therapeutics
Shortens the path to the clinic to increase the probability of success
Expedites to First-In-Human (FIH) clinical trials
Facilitates delivery of medicines to patients worldwide
Startup
Sector:
Biotech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
